ArticleActa parasitologica2026
An ELISA Using a T. gondii GRA6-Derived Peptide as Antigen Successfully Detected Ovine Toxoplasmosis.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii is considered the second most common pathogen causing abortions in sheep, resulting in great economic losses. Thus, timely, sensitive and specific diagnosis of ovine toxoplasmosis is very important. In this study, diagnostic performance of an ELISA using a T. gondii GRA6 peptide (GRA6 ELISA) was investigated using serum samples (n = 61) collected from sheep diagnosed with toxoplasmosis using a commercial ELISA kit. Additionally, an in house ELISA using T. gondii tachyzoite lysate antigen (TLA ELISA) was also used to compare its performance with that of the GRA6 ELISA. Using the commercial ELISA kit as reference, the TLA ELISA and the GRA6 ELISA showed sensitivities of 83.7% and 88.4%, and specificities of 85% and 80.0%, respectively. Cohen's kappa coefficient between TLA ELISA/ GRA6 ELISA and commercial ELISA kit was 0.652 and 0.675, respectively, indicating that both tests have good agreements. When we analyzed serum samples (n = 19) collected from a sheep group that had experienced abortions and were diagnosed with toxoplasmosis using a commercial ELISA kit, sensitivity values for the TLA ELISA and the GRA6 ELISA reached 100% and 89.5%, respectively. According to the seroprevalence results in serum samples analyzed, the commercial ELISA kit detected seroprevalence as 68.2% whereas the GRA6 ELISA and TLA ELISA detected seroprevalence as 66.7% and 61.2%, respectively. Furthermore, among the serum samples that yielded compatible results across the three different ELISA assays (n = 45), 31 were identified as seropositive, corresponding to a seroprevalence rate of 68.9% (31/45). In conclusion, the GRA6 ELISA detected ovine toxoplasmosis with high sensitivity and specificity.
Indexed as
Identifiers
41528606What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.